E Huppertz

597 total citations
28 papers, 373 citations indexed

About

E Huppertz is a scholar working on General Health Professions, Economics and Econometrics and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, E Huppertz has authored 28 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in General Health Professions, 7 papers in Economics and Econometrics and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in E Huppertz's work include Health and Medical Studies (7 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Diabetes Treatment and Management (5 papers). E Huppertz is often cited by papers focused on Health and Medical Studies (7 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Diabetes Treatment and Management (5 papers). E Huppertz collaborates with scholars based in Germany, United Kingdom and United States. E Huppertz's co-authors include Josef Georg Brecht, Hans Hauner, Ingrid Schübert, Ingrid Köster, Peter K. Schädlich, Arin K. Oestreich, H.‐P. Kruse, B Rangoonwala, E Stridde and Lars Pieper and has published in prestigious journals such as BMC Infectious Diseases, Value in Health and PharmacoEconomics.

In The Last Decade

E Huppertz

28 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E Huppertz Germany 12 116 91 84 77 64 28 373
Shiva G. Sajjan United States 14 38 0.3× 91 1.0× 30 0.4× 51 0.7× 178 2.8× 23 469
Susannah Sadler United Kingdom 9 25 0.2× 31 0.3× 41 0.5× 79 1.0× 35 0.5× 20 263
Steven E. Marx United States 16 32 0.3× 54 0.6× 20 0.2× 222 2.9× 65 1.0× 42 701
Andre S. Midgette United States 7 78 0.7× 25 0.3× 61 0.7× 37 0.5× 70 1.1× 9 480
Manon Belhassen France 13 21 0.2× 25 0.3× 97 1.2× 72 0.9× 46 0.7× 70 521
Marloe Prince United States 9 72 0.6× 40 0.4× 32 0.4× 18 0.2× 69 1.1× 22 315
J. del Llano Spain 6 32 0.3× 116 1.3× 54 0.6× 62 0.8× 48 0.8× 9 365
Shejil Kumar Australia 7 79 0.7× 33 0.4× 38 0.5× 36 0.5× 112 1.8× 24 330
Rocco Ferrandino United States 13 141 1.2× 10 0.1× 43 0.5× 76 1.0× 226 3.5× 43 579
Paungpaga Lertdumrongluk Thailand 11 53 0.5× 17 0.2× 28 0.3× 37 0.5× 77 1.2× 16 390

Countries citing papers authored by E Huppertz

Since Specialization
Citations

This map shows the geographic impact of E Huppertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Huppertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Huppertz more than expected).

Fields of papers citing papers by E Huppertz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E Huppertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Huppertz. The network helps show where E Huppertz may publish in the future.

Co-authorship network of co-authors of E Huppertz

This figure shows the co-authorship network connecting the top 25 collaborators of E Huppertz. A scholar is included among the top collaborators of E Huppertz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E Huppertz. E Huppertz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Köster, Ingrid, E Huppertz, Hans Hauner, & Ingrid Schübert. (2014). Costs of Diabetes Mellitus (CoDiM) in Germany, Direct Per-capita Costs of Managing Hyperglycaemia and Diabetes Complications in 2010 Compared to 2001. Experimental and Clinical Endocrinology & Diabetes. 122(9). 510–516. 39 indexed citations
2.
Porzsolt, Franz, E Huppertz, Axel Mühlbacher, et al.. (2013). Die angemessene Evidenz für Therapieentscheidungen: eine Diskussion des Methodenpluralismus in klinischen Studien. Gesundheitsökonomie & Qualitätsmanagement. 18(1). 31–39. 1 indexed citations
3.
Hampl, Monika, et al.. (2011). Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre. BMC Infectious Diseases. 11(1). 73–73. 13 indexed citations
4.
Köster, Ingrid, E Huppertz, Hans Hauner, & Ingrid Schübert. (2011). Direct Costs of Diabetes Mellitus in Germany – CoDiM 2000–2007. Experimental and Clinical Endocrinology & Diabetes. 119(6). 377–385. 68 indexed citations
5.
Huppertz, E. (2011). Krankheitskostenstudien bei Diabetes mellitus. Der Diabetologe. 7(2). 80–87. 1 indexed citations
6.
Huppertz, E, Lars Pieper, Jens Klotsche, et al.. (2008). Diabetes Mellitus in German Primary Care: Quality of Glycaemic Control and Subpopulations not well Controlled – Results of the DETECT Study. Experimental and Clinical Endocrinology & Diabetes. 117(1). 6–14. 30 indexed citations
7.
Rathmann, Wolfgang, et al.. (2007). Prescription of Insulin Glargine in Primary Care Practices in Germany. Experimental and Clinical Endocrinology & Diabetes. 115(4). 252–256. 5 indexed citations
8.
Schmidt‐Lucke, Caroline, E Huppertz, Walter Lehmacher, et al.. (2007). Economic Evaluation of Enoxaparin for Anticoagulation in Early Cardioversion of Persisting Nonvalvular Atrial Fibrillation. American Journal of Cardiovascular Drugs. 7(3). 199–217. 7 indexed citations
9.
Schädlich, Peter K., et al.. (2006). Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients. PharmacoEconomics. 24(6). 571–591. 19 indexed citations
10.
Maxion‐Bergemann, Stefanie, et al.. (2005). Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the ?Diabetes Mellitus Model?. International Journal of Clinical Pharmacology and Therapeutics. 43(6). 271–281. 7 indexed citations
11.
Schädlich, Peter K., H. Zeidler, A. Zink, et al.. (2005). Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany. PharmacoEconomics. 23(4). 377–393. 6 indexed citations
12.
Schädlich, Peter K., H. Zeidler, A. Zink, et al.. (2005). Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany. PharmacoEconomics. 23(4). 395–420. 17 indexed citations
13.
Huppertz, E, et al.. (2005). PDB32 ECONOMIC EVALUATION OF THE LAPTOP-STUDY RESULTS. Value in Health. 8(6). A164–A164. 1 indexed citations
14.
Brecht, Josef Georg, et al.. (2004). Health-economic comparison of three recommended drugs for the treatment of osteoporosis.. PubMed. 24(1). 1–10. 33 indexed citations
15.
Schädlich, Peter K., Josef Georg Brecht, B Rangoonwala, & E Huppertz. (2004). Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events. PharmacoEconomics. 22(15). 955–973. 17 indexed citations
16.
Brecht, Josef Georg, et al.. (2003). Pharmacoeconomic analysis of osteoporosis treatment with risedronate.. PubMed. 23(4). 93–105. 21 indexed citations
17.
18.
19.
Schädlich, Peter K., Josef Georg Brecht, Massimo Brunetti, et al.. (2001). Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension. PharmacoEconomics. 19(5). 497–512. 24 indexed citations
20.
Schädlich, Peter K., E Huppertz, & Josef Georg Brecht. (1998). Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction. PharmacoEconomics. 14(6). 653–669. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shiva G. Sajjan Breakdown of academic impact, for papers by Susannah Sadler Breakdown of academic impact, for papers by Steven E. Marx Breakdown of academic impact, for papers by Andre S. Midgette Breakdown of academic impact, for papers by Manon Belhassen Breakdown of academic impact, for papers by Marloe Prince Breakdown of academic impact, for papers by J. del Llano Breakdown of academic impact, for papers by Shejil Kumar Breakdown of academic impact, for papers by Rocco Ferrandino Breakdown of academic impact, for papers by Paungpaga Lertdumrongluk
Rankless by CCL
2026